8-K: Axsome Therapeutics Secures $570 Million Credit Facility with Blackstone, Retires Existing Debt

Axsome Therapeutics enters into a $570 million term loan and revolving credit facility with Blackstone, retiring its previous debt with Hercules Capital and strengthening its financial position.

Summary

• Axsome Therapeutics has entered into a $570 million credit facility with Blackstone, consisting of a term loan and a revolving credit facility.
• The company used part of the term loan to retire its previous debt with Hercules Capital.
• The new facility includes a $500 million term loan and a $70 million revolving credit facility.
• Axsome drew down $120 million from the term loan upon closing to retire the Hercules Capital loan.
• An additional $250 million may be drawn at Axsome's option, with another $200 million available subject to Blackstone's approval.
• The term loan bears interest at SOFR plus 4.75%, while the revolving credit facility bears interest at SOFR plus 4.0%.
• The facility matures in May 2030 and has a 60-month interest-only payment period.
• Concurrent with the agreement, Blackstone purchased $15 million of Axsome common stock at $107.14 per share.
• The loan agreement contains a minimum liquidity covenant of $30 million, tested quarterly.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the improved financial terms of the new credit facility, the partnership with Blackstone, and the expectation of reduced interest expenses. The successful refinancing and capital injection are viewed favorably.

Positives

• The new credit facility expands Axsome's available credit by over $200 million.
• The agreement is expected to significantly reduce interest expenses.
• The partnership with Blackstone provides access to their expertise in the life sciences industry.
• The improved terms of the new facility support accelerating time to profitability and enhancing shareholder value.
• The facility includes a 60-month interest-only payment period, providing flexibility in the near term.

Negatives

• The loan agreement contains a minimum liquidity covenant of $30 million, tested quarterly, which could restrict financial flexibility if not maintained.
• The loans are subject to mandatory prepayment provisions upon certain events like a change of control or asset sales.

Risks

• Failure to maintain the minimum liquidity covenant of $30 million could trigger an event of default.
• Mandatory prepayment provisions could be triggered by unforeseen events, requiring early repayment of the loans.
• The availability of the additional $200 million under the term loan facility is subject to Blackstone's approval.

Future Outlook

The company expects the new facility to result in a significant reduction in interest expense and support its next phase of growth. Axsome aims to accelerate time to profitability and enhance shareholder value.

Management Comments

• 'The improved financial terms and expected use of the new facility are expected to result in a significant reduction in interest expense,' said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.
• 'We are pleased to partner with the Blackstone team given their differentiated expertise in the life sciences industry.'
• 'The improved terms of the new facility underscore our commitment to accelerating time to profitability and enhancing shareholder value, while advancing our mission to improve the lives of patients living with serious CNS disorders.'

Industry Context

This announcement reflects a trend in the biopharmaceutical industry where companies seek flexible financing solutions to support growth and commercialization efforts. Partnering with specialized investors like Blackstone Life Sciences provides not only capital but also industry expertise.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical sector often utilize term loans and revolving credit facilities to fund clinical trials, commercial launches, and acquisitions.
• The interest rates on the Axsome facility (SOFR plus 4.75% and SOFR plus 4.0%) are within the typical range for similar loans in the current market environment, but the exact rate depends on the company's credit profile and the specific terms negotiated.
• Other companies like Biohaven Pharmaceutical Holding Company Ltd. have secured similar financing arrangements to support their commercial operations and pipeline development.

Related Party Transactions

• Blackstone purchased $15 million of Axsome common stock at $107.14 per share, concurrent with the closing of the credit facility.

Stakeholder Impact

• Shareholders are expected to benefit from the reduced interest expenses and improved financial flexibility.
• The company's ability to invest in research and development and commercialization efforts is enhanced, potentially benefiting patients.
• Employees may experience increased job security due to the company's strengthened financial position.

Next Steps

• File the Loan Agreement and Purchase Agreement as exhibits to the company's next periodic report with the SEC.
• Monitor compliance with the minimum liquidity covenant of $30 million.
• Potentially draw down additional funds from the term loan facility as needed, subject to Blackstone's approval.

Key Dates

Keywords

credit facility, term loan, revolving credit, Blackstone, Axsome Therapeutics, financing, debt, CNS disorders, biopharmaceutical